PTC Therapeutics, Inc. Proceeds from Issuance of Convertible Preferred Stock
PTC Therapeutics, Inc. (PTCT) reported Proceeds from Issuance of Convertible Preferred Stock of $29.36 million for the 12-month period ending 2012-12-31, per its 10-K filed 2015-03-02.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2015-03-02
- PTC Therapeutics, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2012-12-31 was $248.00.
- PTC Therapeutics, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2012-09-30 was -$77.49K.
- PTC Therapeutics, Inc. proceeds from issuance of convertible preferred stock for fiscal 2012 was $29.36M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month | Proceeds from Issuance of Convertible Preferred Stock 12 month as first filed |
|---|---|---|---|---|---|
| 2012-12-31 | $248.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$77.24K derived: sum of 2 quarters · filed 2015-03-02 | $29.36M 10-K · filed 2015-03-02 | $29.35M 10-K · filed 2014-03-06 | |
| 2012-09-30 | -$77.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $29.35M 10-Q · filed 2013-11-14 | |||
| 2012-06-30 | $29.43M 10-Q · filed 2013-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |